Articles & Issues
- Language
- English
- Conflict of Interest
- In relation to this article, we declare that there is no conflict of interest.
- Publication history
-
Received December 30, 2008
Accepted January 12, 2009
-
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/bync/3.0) which permits
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright © KIChE. All rights reserved.
All issues
Characterization of solvent induced crystalline and amorphous homoharringtonine
Department of Chemical Engineering, Kongju National University, 182, Shinkwan-dong, Kongju, Chungnam 314-701, Korea
Korean Journal of Chemical Engineering, July 2009, 26(4), 1090-1093(4), 10.1007/s11814-009-0181-z
Download PDF
Abstract
The morphologies of homoharringtonine were conveniently controlled by solvent treatment and the morphologies of homoharringtonine were characterized by XRD and SEM. Crystalline homoharringtonine was simply made by dissolving homoharringtonine in a special polar solvent containing a small amount of water (methanol/water=98/2, v/v). On the other hand, amorphous homoharringtonine was made by dissolving homoharringtonine in relatively non-polar solvent (methylene chloride/methanol=98/2, v/v). Amorphous homoharringtonine, with a fine particle size, was obtained by dissolving in methylene chloride/methanol (98/2, v/v), following by spray drying. Also, residual solvents, methanol and methylene chloride, were easily removed to less than concentration limit in ICH (International Conference on Harmonisation) guidance by spray drying and successive drying in a vacuum oven. Amorphous homoharringtonine was more soluble in water than crystalline homoharringtonine, and the water content of amorphous homoharringtonine was less changeable than crystalline homoharringtonine at given humidity (95 RH%) during storage. This information is very useful for production and quality control of pharmaceuticals in the commercialization step.
Keywords
References
Grem JL, Cheson BD, King SA, Leyland-Jones B, Suffness M, J. Natl. Cancer Inst., 80, 1095 (1988)
He J, Cheung AP, Wang E, Struble E, Fang K, Nguyen N, Liu P, J. Pharm. Biomed. Anal., 22, 541 (2000)
Jin J, Jiang DZ, Mai WY, Meng HT, Qian WB, Tong HY, Huang J, Mao LP, Tong Y, Wang L, Chen ZM, Xu WL, Leukemia, 3, 1361 (2006)
Xie WZ, Lin MF, Huang H, Cai Z, Am. J. Chin. Med., 34, 233 (2006)
Luo CY, Tang JY, Wang YP, Hematology, 9, 259 (2004)
Zhou DC, Zittoun R, Marie JP, Bull. Cancer, 82, 987 (1995)
Marin D, Kaeda JS, Andreasson C, Saunders SM, Bua M, Olavarria E, Goldman JM, Apperley JF, Cancer, 103, 1850 (2005)
Visani G, Russo D, Ottaviani E, Tosi P, Damiani D, Michelutti A, Manfroi S, Baccarani M, Tura S, Leukemia, 11, 624 (1997)
O’Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM, Cancer, 98, 888 (2003)
Efferth T, Davey M, Olbrich A, Rucker G, Gebhart E, Davey R, Blood Cells Mol. Dis., 28, 160 (2002)
Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O’Brien SM, Cancer, 15, 1591 (2001)
Keller L, Dumas F, d’Angelo J, Tetrahedron Lett., 42, 1911 (2001)
Kim BS, Kim JH, Korean J. Chem. Eng., 25(1), 108 (2008)
Chiou WL, Riegelman S, J. Pharm. Sci., 60, 1281 (1971)
Kim JH, Korean J. Biotechnol. Bioeng., 21, 1 (2006)
Park SS, Kang HY, Korean J. Chem. Eng., 25(1), 78 (2008)
Sharma US, Baulausbramanaian SV, Straubinger RM, J. Pharm. Sci., 84, 1223 (1995)
ICH guidance Q3C impurities: Residual solvents, Federal register, 62(247), 67378 (1997)
Hancock BC, Parks M, Pharm. Res., 17, 397 (2000)
Gi US, Min B, Lee JH, Kim JH, Korean J. Chem. Eng., 21(4), 816 (2004)
He J, Cheung AP, Wang E, Struble E, Fang K, Nguyen N, Liu P, J. Pharm. Biomed. Anal., 22, 541 (2000)
Jin J, Jiang DZ, Mai WY, Meng HT, Qian WB, Tong HY, Huang J, Mao LP, Tong Y, Wang L, Chen ZM, Xu WL, Leukemia, 3, 1361 (2006)
Xie WZ, Lin MF, Huang H, Cai Z, Am. J. Chin. Med., 34, 233 (2006)
Luo CY, Tang JY, Wang YP, Hematology, 9, 259 (2004)
Zhou DC, Zittoun R, Marie JP, Bull. Cancer, 82, 987 (1995)
Marin D, Kaeda JS, Andreasson C, Saunders SM, Bua M, Olavarria E, Goldman JM, Apperley JF, Cancer, 103, 1850 (2005)
Visani G, Russo D, Ottaviani E, Tosi P, Damiani D, Michelutti A, Manfroi S, Baccarani M, Tura S, Leukemia, 11, 624 (1997)
O’Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM, Cancer, 98, 888 (2003)
Efferth T, Davey M, Olbrich A, Rucker G, Gebhart E, Davey R, Blood Cells Mol. Dis., 28, 160 (2002)
Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O’Brien SM, Cancer, 15, 1591 (2001)
Keller L, Dumas F, d’Angelo J, Tetrahedron Lett., 42, 1911 (2001)
Kim BS, Kim JH, Korean J. Chem. Eng., 25(1), 108 (2008)
Chiou WL, Riegelman S, J. Pharm. Sci., 60, 1281 (1971)
Kim JH, Korean J. Biotechnol. Bioeng., 21, 1 (2006)
Park SS, Kang HY, Korean J. Chem. Eng., 25(1), 78 (2008)
Sharma US, Baulausbramanaian SV, Straubinger RM, J. Pharm. Sci., 84, 1223 (1995)
ICH guidance Q3C impurities: Residual solvents, Federal register, 62(247), 67378 (1997)
Hancock BC, Parks M, Pharm. Res., 17, 397 (2000)
Gi US, Min B, Lee JH, Kim JH, Korean J. Chem. Eng., 21(4), 816 (2004)
